Age-Related Molecular Degeneration Market Report 2023: R&D Consistency Drives Sector GrowthPosted by Ganesh Shinde on January 20th, 2023 The global age-related molecular degeneration market is currently valued at US$ 11.28 Million in 2023 and is anticipated to expand at a CAGR of 7%. Owing to the technological advances in healthcare the market is likely to propel to US.19 Million by 2033. The increasing prevalence of AMD and a strong product pipeline are anticipated to be the major drivers for the growth of age-related molecular degeneration market. According to the WHO, around 196 million people were affected by age-related macular degeneration globally in 2020, including over 10.4 million moderate-to-severe vision impairment cases. Globally, advanced age-related macular degeneration is the primary factor in irreversible blindness and visual impairment. As a result, the market for age-related macular degeneration is anticipated to experience significant growth over the forecast period. Most severe eye conditions are rising globally, and vision loss is becoming a significant public health issue and increase in the prevalence of the retinal disorder in many developed and developing nations drive market growth. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.9% over the forecast period. Competitive Landscape Browse More@ https://www.futuremarketinsights.com/reports/age-related-macular-degeneration-market More Valuable Insights Available The study divulges essential insights on the age related molecular degeneration market by Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy) by Region - Global Forecast 2023-2033 Like it? Share it!More by this author |